<DOC>
	<DOCNO>NCT00179244</DOCNO>
	<brief_summary>The purpose study evaluate comparative effectiveness Risperdal ( risperidone ) bupropion ER ( extended release ) combine SSRI medication test relative safety combination .</brief_summary>
	<brief_title>Risperidone vs. Bupropion ER Augmentation SSRIs Treatment-Resistant Depression</brief_title>
	<detailed_description>Major depression severe disorder serious consequence . Effective treatment available ; however , clinical trial 30-40 % patient experience even 50 % reduction depression severity score , 50-70 % fail achieve full therapeutic response . Futhermore , impairment disorder continue essentially unabated patient treat fully remit . If anything , situation least bad bad clinical practice . Clearly , alternative need manage common clinical condition . The addition bupropion ER ( extended release ) SSRI empirical support , become common augmentation strategy US . A comparative trial combination risperidone bupropion ER add SSRI treatment resistant deperssion could help support risperidone condition ; trial seem warranted time . Patients currently SSRI adequate dosage least 3 week response , randomly assign ( open-label ) either risperidone bupropion ER augmentation period 6 week . Patients follow weekly begin bi-weekly towards end trial compare response group .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Male female 18 year old DSMIV diagnosis major depressive disorder least moderate severity , without psychotic feature HamD 17 score 18 Have documentable history 2 prior adequate trial antidepressant include SSRI without sufficient response . A clinically adequate trial define take minimum effective dose antidepressant least 3 week without significant change depressive symptom . Must currently serotonin uptake inhibitor ( include venlafaxine duloxetine ) adequate dose least 3 week . Ability willingness provide consent participation study . Any medical condition would preclude treatment SSRI , risperidone , bupropion ER Any clinically significant unstable medical condition Diagnosis bipolar disorder primary diagnosis psychotic disorder Current psychotic symptom ( hallucination delusion ) Alcohol drug abuse dependence last 3 month ( exclude nicotine caffeine dependence/abuse ) abuse within last month Documented nonresponse combination novel antipsychotic bupropion ER SSRI Concomitant use psychotropic SSRI zolpidem ( PRN sleep ) Score 4 suicide item HamD scale determination investigator significant suicide risk Known sensitivity risperidone bupropion ER</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Treatment Resistant Depression</keyword>
</DOC>